Appendix:

**Association Between SARS-CoV-2 RNAemia and Post-Acute Sequelae of COVID-19.**

Nikhil Ram-Mohan PhD1, David Kim MD PhD1, Angela J Rogers MD MPH2, Catherine A Blish MD PhD3, Kari C Nadeau MD PhD2, Andra L Blomkalns MD1, Samuel Yang MD1\*

1 Department of Emergency Medicine, Stanford University School of Medicine, Palo Alto CA 94305 USA

2 Department of Medicine - Pulmonary, Allergy & Critical Care Medicine, Stanford University School of Medicine, Palo Alto CA 94305 USA

3 Department of Medicine/Infectious Diseases, Stanford University School of Medicine, Palo Alto CA 94305 USA

\* Correspondence to:

Samuel Yang

syang5@stanford.edu

(650) 725-9492

**Table S1. Logistic model of PASC risk.**

|  |  |  |
| --- | --- | --- |
| **Variable** | **Odds Ratio** | **95% CI** |
| Age | 0.99 | 0.99 – 1.00 |
| Male | 0.89 | 0.76 – 1.03 |
| Disease severity at enrollment (reference = mild) |  |  |
|  Moderate | 1.10 | 0.92 – 1.32 |
|  Severe | 1.24 | 0.84 – 1.83 |
| Duration of symptoms by enrollment | 1.01 | 0.96 – 1.02 |
| **RNAemia at enrollment** | **1.31** | **1.08 – 1.59** |
| Symptomatic at enrollment | 1.28 | 0.89 – 1.83 |

n=155

Potential predictors of Post-Acute Sequelae of COVID-19 (PASC) at follow-up included: age, gender, severity of disease upon enrollment (mild = discharged from ED, moderate = hospitalized, requiring no more than oxygen by nasal cannula, and severe = hospitalized, requiring high-flow nasal cannula or mechanical ventilation), duration of symptoms upon enrollment, RNAemia at enrollment, and presence of any symptom at enrollment (anxiety, dizziness, fatigue, hair loss, palpitations, rash, insomnia, chest pain, chills, cough, decrease in sense of taste, fever, nausea/vomiting/diarrhea, headache, loss of smell, myalgia, new confusion, shortness of breath).